Predicting oral absorption of drugs: A case study with a novel class of antimicrobial agents

Pharmaceutical Research

Volumn 20, Issue 8, 2003, Pages 1149-1155

  Hilgers, Allen R ^a   Smith, Donald P ^b   Biermacher, John J ^b   Day, Jeffrey S ^a   Jensen, Jana L ^b   Sims, Sandra M ^b   Adams, Wade J ^c   Friis, Janice M ^c   Palandra, Joe ^c   Hosley, John D ^c   Shobe, Eric M ^c   Burton, Philip S ^a  

^a Drug Absorption and Transport   (United States)

^b Pharmacia   (United States)

^c Pharmacia   (United States)

Author keywords

Biopharmaceutics; Caco 2 cell; In vitro in vivo; Oral absorption; Prediction; Solubility

Indexed keywords

CYCLOSPORIN; EPEREZOLID; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PNU 101603; PNU 173335; PNU 173995; PNU 176723; PNU 176839; PNU 177553; PNU 177780; PNU 179397; PNU 179398; PNU 179399; PNU 179450; PNU 179759; PNU 179954; PNU 179962; PNU 182347; PNU 182945; PNU 183981; PNU 184147; PNU 184148; PNU 184249; PNU 184421; PNU 184435; PNU 184470; PNU 241028; PNU 93936A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; CALCULATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SOLUBILITY; EVALUATION; INTERMETHOD COMPARISON; INTESTINE ABSORPTION; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; INTESTINE VOLUME; MAXIMUM ABSORBABLE DOSE; MAXIMUM ALLOWABLE CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SOLUTE; SOLUTE SOLUBILITY; STATISTICAL SIGNIFICANCE; VOLUMETRY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; OXAZOLIDINONES; RATS; SOLUBILITY; SOLVENTS;

EID: 12444301371     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025084527878     Document Type: Article

References (20)

1. G. W. Caldwell. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Curr. Opin. Drug Dis. Develop. 3:30-41 (2000).
2. S. Venkatesh and R. A. Lipper. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:145-154 (2000).
3. C. A. Lipinski, F. Lombordo, B. W. Dominy, and P. J. Freeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23:3-25 (1997).
4. D. Roy, F. Ducher, A. Laumain, and J. Y. Legendre. Determination of the aqueous solubility of drugs using a convenient 96-well plate-based assay. Drug Develop. Ind. Pharm. 27:107-109 (2001).
5. S. H. Chong, S. A. Dando, and R. A. Morrison. Evaluation of Biocoat® intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm. Res. 14:1835-1837 (1997).
6. M. Bertrand, P. Jackson, and B. Walther. Rapid assessment of drug metabolism in the drug discovery process. Eur. J. Pharm. Sci. 11(Suppl 2):S61-S72 (2000).
7. K. C. Johnson and A. C. Swindell. Guidance in the setting of drug particle size specification to minimize variability in absorption. Pharm. Res. 13:1795-1798 (1996).
8. W. Curatolo. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today 1:387-393 (1998).
9. L. D. Dresser and M. J. Rybak. The pharmacologic and bateriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18:456-462 (1998).
10. M. J. Genin, D. A. Allwine, D. J. Anderson, M. R. Barbachyn, D. E. Emmert, S. A. Garmon, D. R. Graber, K. C. Grega, J. B. Hester, D. K. Hutchinson, J. Morris, R. J. Reischer, C. W. Ford, G. E. Zurenko, J. C. Hamel, R. D. Schaadt, D. Stapert, and B. H. Yagi. Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. J. Med. Chem. 43:953-970 (2000).
11. A. R. Hilgers, R. A. Conradi, and P. S. Burton. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 9:902-910 (1990).
12. J. S. Bourdage, P. S. Burton, C. J. Cole, R. A. Conradi, J. S. Day, A. R. Hilgers, and W. P. Pfund. Characterization of the Caco-2 permeability model and rat intestinal perfusion model for use With the Biopharmaceutics Classification System. AAPS Pharm-Sci 1999 AAPS Annual Meeting Supplement. 1999; 1 (4) Available from: http://www.aapspharmaceutica.com/ scientificjournals/pharmsci/am_abstracts/1999/2419.htm.
13. J. Taipalensuu, H. Tornblom, G. Lindberg, C. Einarsson, F. Sjoqvist, H. Melhus, P. Garberg, B. Sjostrom, B. Lundgren, and P. Artursson. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299:164-170 (2001).
14. H. Gutmann, G. Fricker, M. Torok, S. Michael, C. Beglinger, and J. Drewe. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm. Res. 16:402-407 (1999).
15. C. Wandel, R. B. Kim, S. Kajiji, F. P. Guengerich, G. R. Wilkinson, and A. J. J. Wood. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potentcies. Cancer Res. 59:3944-3948 (1999).
16. 2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288:171-179 (1999).
17. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880-885 (1991).
18. nd Edition, Marcel Dekker, New York, 1990, pp 23-90.
19. D. Hortar and J. B. Dressman. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 25:3-14 (1997).
20. V. J. Stella, S. Martodihardjo, K. Tarada, and V. M. Rao. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications. J. Pharm. Sci. 87:1235-1241 (1998).